Compare CIVB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | KMDA |
|---|---|---|
| Founded | 1884 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.4M | 458.6M |
| IPO Year | N/A | N/A |
| Metric | CIVB | KMDA |
|---|---|---|
| Price | $23.84 | $8.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $26.00 | $13.00 |
| AVG Volume (30 Days) | ★ 97.6K | 76.2K |
| Earning Date | 01-29-2026 | 03-04-2026 |
| Dividend Yield | ★ 3.02% | 2.35% |
| EPS Growth | ★ 31.34 | 30.41 |
| EPS | ★ 2.64 | 0.35 |
| Revenue | $169,173,000.00 | ★ $174,787,000.00 |
| Revenue This Year | $15.24 | $14.79 |
| Revenue Next Year | $6.52 | $11.38 |
| P/E Ratio | ★ $9.03 | $23.80 |
| Revenue Growth | ★ 13.47 | 10.36 |
| 52 Week Low | $17.47 | $5.54 |
| 52 Week High | $25.59 | $8.88 |
| Indicator | CIVB | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 61.67 |
| Support Level | $23.35 | $7.94 |
| Resistance Level | $25.40 | $8.71 |
| Average True Range (ATR) | 0.82 | 0.24 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 43.50 | 61.09 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.